TB-500 Spray10mg
TB-500 Spray Canada — Nasal Spray
Thymosin Beta-4 Fragment Peptide
TB-500 is a synthetic peptide corresponding to an active region of thymosin beta-4, a naturally occurring actin-binding protein. Analytical work has characterised the material sold under this name as an N-terminally acetylated fragment of the thymosin beta-4 sequence. It is supplied here as a spray-format preparation for laboratory research only.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
TB-500 is a synthetic peptide corresponding to an active region of thymosin beta-4, a naturally occurring actin-binding protein. Analytical work has characterised the material sold under this name as an N-terminally acetylated fragment of the thymosin beta-4 sequence. It is supplied here as a spray-format preparation for laboratory research only.
In scientific literature, TB-500 appears primarily in two contexts: analytical chemistry work developing detection and quantification methods in biological matrices, and a small number of preclinical models examining actin-related and tissue repair signalling. The published record is limited, and much of it is methodological rather than mechanistic.
Thymosin beta-4 is characterised in the literature as a G-actin sequestering protein involved in cytoskeletal organisation and cell migration. TB-500 is a shorter synthetic sequence derived from the region of that protein associated with actin binding, and analytical characterisation has confirmed that commercial TB-500 material corresponds to an acetylated fragment of the parent sequence rather than the full-length protein. The extent to which the fragment reproduces the signalling behaviour of full-length thymosin beta-4 is not firmly established in the published record.
Research endpoints evaluated to date include metabolite profiling and in vitro wound closure screening, detection of the peptide and its degradation products in equine urine and plasma, adsorption behaviour of the peptide during sample handling, and a rat Achilles tendon model assessed by histopathological and biomechanical measures. Several recent review articles discuss TB-500 within broader surveys of injectable peptides in orthopaedic, sports medicine and regenerative medicine contexts, generally noting that controlled human evidence is absent.
TB-500 entered the scientific literature largely through anti-doping analytical chemistry. Work published in 2012 synthesised and characterised the N-terminal acetylated fragment identified in material marketed as TB-500, establishing what the commercial compound actually consists of, and separate 2012 work developed liquid chromatography mass spectrometry methods for detecting it in equine urine and plasma. Subsequent analytical studies addressed adsorption losses during handling of doping-relevant peptides including TB-500, and broader method development for emerging non-approved compounds in human doping controls.
Preclinical investigation has been comparatively sparse. A 2024 study quantified TB-500 and its metabolites in in vitro systems and in rats and screened the resulting fragments for wound healing activity in vitro. A rat Achilles tendon study compared TB-500 and BPC-157 using histopathological and biomechanical endpoints. Review literature from the orthopaedic, sports medicine and gerontology fields has since catalogued the compound, consistently characterising it as unapproved and lacking controlled clinical data.
TB-500 appears in two distinct research frameworks. The first is analytical and forensic: method development for identifying the peptide and its metabolites in biological matrices, characterisation of the acetylated fragment present in commercial material, and investigation of adsorption behaviour affecting quantification. The second is preclinical tissue repair research, represented by a small number of animal and in vitro studies examining actin-related signalling and wound or tendon healing endpoints. Review articles place the compound within wider discussions of unregulated injectable peptides, noting the absence of controlled human trial data.
4 of the 5 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Rahaman 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on actin, binding or cytoskeletal. This heading marks where TB-500 Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Biçer 2026, Rahaman 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Rahaman 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Esposito 2012, Ho 2012, Rahaman 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 6 primary papers published between 2012 and 2026 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
TB-500 Spray is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for TB-500 Spray, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
TB-500 Spray is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under analytical detection and metabolite profiling, actin-binding and cytoskeletal signalling models and preclinical tendon healing models.
The 6 papers cited on this page, published between 2012 and 2026 (2 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for TB-500 Spray is per lot, not per product. The current 10mg lot TB5-CA-26F-10 returned 99.182% purity, 11.52 mg measured, 115.2% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for TB-500 Spray. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy TB-500 Spray in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
TB-500 Spray ships as a prepared solution rather than as lyophilized powder, so it is already past the point at which a powder would be reconstituted. That shortens handling but tightens storage: a compound in solution is less stable than the same compound dry, and refrigeration from arrival onward is the relevant control.
The stability window for a solution is shorter than the shelf life of a sealed lyophilized vial of the same compound. Records for laboratory work in this format should note the date the unit was opened, not only the date it was received.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each spray unit contains the labeled quantity of TB-500 in solution. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the compound as supplied. Any laboratory materials required for handling, dilution, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
PubMedDoping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry
PubMedSimultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
PubMedEffects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
PubMedAdsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5
PubMedSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
